Celonic and CureVac Announce Agreement to Manufacture over 100 Million Doses of CureVac’s COVID-19 Vaccine Candidate, CVnCoV
Celonic
PR-M03-21-006Mar 30, 2021
Clinical Trials
CureVac Reports Positive Interim Phase 1 Data for its COVID-19 Vaccine Candidate, CVnCoV
CureVac AG
PR-M11-20-002Nov 02, 2020
COVID-19
CureVac Expected to Receive up to 252 million Euros from the German Federal Ministry of Research for Further COVID-19 Vaccine Development
CureVac AG
PR-M09-20-NI-05Sep 04, 2020
Vaccine Production
Tesla to Make Molecule Printers for German COVID-19 Vaccine Developer CureVac
CureVac AG
PR-M07-20-NI-002Jul 03, 2020
Leadership
Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG
CureVac AG
PR-M03-20-NI-023Mar 12, 2020